Ophtascan™ - mobile Cancer screening
Clinically tested and validated
Ophtascan™ is a mobile in real time cancer screening AI driven technology, clinically tested, validated and ready to be launched with a proper corporate partner. Close to 1000 patients have been tested.
Cancer screening focus
Ophtascan™ targets all four stages of cancer in: lungs, liver, uterus, prostate and breast
Mobile application ready
Ophtascan™ gives diagnose feedback within 25 sec, with a precision hit-rate over 96%. The mobile application is ready to be integrated .
Diabetes R&D
Ophtascan™ is currently being used to screen Diabetes type 2 , where over 100 patient study is completed with a sold success. The precision hit rate is increasing with every patient and the AI application will be ready to launch in q2 2021.